NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 127 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24 | -72.7% | 21,975 | +2.4% | 0.00% | -100.0% |
| Q1 2023 | $88 | +22.2% | 21,460 | +49.3% | 0.00% | 0.0% |
| Q4 2022 | $72 | -99.9% | 14,374 | +35.1% | 0.00% | -50.0% |
| Q3 2022 | $139,000 | -7.3% | 10,642 | -9.2% | 0.00% | 0.0% |
| Q2 2022 | $150,000 | -83.1% | 11,719 | -79.9% | 0.00% | -71.4% |
| Q1 2022 | $887,000 | -33.8% | 58,160 | -23.1% | 0.01% | 0.0% |
| Q4 2021 | $1,340,000 | +165.9% | 75,670 | +215.6% | 0.01% | +250.0% |
| Q3 2021 | $504,000 | -31.0% | 23,978 | -35.2% | 0.00% | -33.3% |
| Q2 2021 | $730,000 | +484.0% | 36,993 | +757.1% | 0.00% | +200.0% |
| Q1 2021 | $125,000 | -85.5% | 4,316 | -84.8% | 0.00% | -80.0% |
| Q4 2020 | $860,000 | +362.4% | 28,375 | +142.5% | 0.01% | +400.0% |
| Q3 2020 | $186,000 | -88.6% | 11,700 | -85.8% | 0.00% | -92.9% |
| Q2 2020 | $1,626,000 | +1150.8% | 82,348 | +683.8% | 0.01% | +1300.0% |
| Q1 2020 | $130,000 | +28.7% | 10,506 | +91.9% | 0.00% | 0.0% |
| Q4 2019 | $101,000 | – | 5,476 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |